LSE-AIM$MXCT
Maxcyte Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
MaxCyte's financial performance increased in Q3 2024, driven by strong core revenue growth and increasing demand for its platform.
MaxCyte reported a 2% increase in total revenue, reaching $8.2 million in Q3 2024. Core business revenue grew by 23% to $8.1 million, driven by a 39% increase in cell therapy revenue. The company signed six new SPL clients year-to-date, bringing the total to 29. MaxCyte is also evaluating cost reduction opportunities, including a potential cancellation of its AIM listing.
- Total revenue increased by 2% to $8.2 million in Q3 2024.
- Core business revenue increased by 23% to $8.1 million in Q3 2024.
- Cell therapy revenue increased by 39% to $6.5 million in Q3 2024.
- Six new SPL clients signed year-to-date, bringing the total to 29.
Headline financials
Revenue & EPS history
Maxcyte · Revenue · Quarterly
$8.16M
Revenue by segment
Maxcyte · $1.4M total across 1 segment · Q3 2023
- Program-Related$1.4M+86.2%100.0%
Forward guidance
MaxCyte expects full year 2024 core business revenue to grow at least 5% compared to 2023. SPL Program-related revenue is expected to be approximately $6 million. The company anticipates ending 2024 with approximately $185 million in total cash, cash equivalents and investments.
Tailwinds
- Full year 2024 core business revenue is expected to grow at least 5% compared to 2023.
- SPL Program-related revenue is expected to be approximately $6 million.
- Company anticipates ending 2024 with approximately $185 million in total cash, cash equivalents and investments.
- Strong core revenue growth driven by commercial execution.
- Increasing demand for the ExPERT platform.
Headwinds
- Full year outlook does not include SPL Program-related revenue from Vertex/CRISPR’s CASGEVYTM.
- Considering the costs and benefits of maintaining dual listings on AIM and Nasdaq.
- Potential cancellation of the admission of its common stock from trading on AIM.
- Gross margin decreased from 90% to 76%.
- Net loss of $11.6 million compared to net loss of $11.3 million for the same period in 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2024
+291.3%
Avg return
Earnings day
-2.8%
Avg return
5 days after
+220.5%
Avg return
30 days after
42%
10 / 24 earnings
Positive
+7042.3%
Q1 2025
Best reaction
-29.9%
Q2 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +24.1% | +29.0% | — | |
| Q3 2025 | -12.0% | -7.2% | -12.0% | |
| Q2 2025 | -29.9% | -37.7% | -30.9% | |
| Q1 2025 | +7042.3% | -19.7% | -21.5% | |
| Q4 2024 | -8.4% | -6.1% | +5251.6% | |
| Q3 2024 | +0.5% | -7.3% | -6.7% | |
| Q2 2024 | +2.5% | -3.7% | -8.8% | |
| Q1 2024 | +0.5% | +21.2% | +23.5% | |
| Q4 2023 | +0.3% | +8.6% | +4.0% | |
| Q3 2023 | -1.5% | +2.4% | +42.6% | |
| Q2 2023 | -2.7% | -14.3% | -17.4% | |
| Q1 2023 | -0.6% | -19.2% | -2.8% | |
| Q4 2022 | +2.7% | +2.4% | +30.8% | |
| Q3 2022 | -9.4% | +3.0% | -19.9% | |
| Q2 2022 | +3.6% | +4.9% | +16.4% | |
| Q1 2022 | -4.3% | -13.0% | -12.9% | |
| Q1 2021 | -4.3% | -13.0% | -12.9% | |
| Q4 2021 | +3.4% | +6.7% | -23.7% | |
| Q4 2019 | +3.4% | +6.7% | -23.7% | |
| Q3 2020 | -7.7% | +3.8% | -9.7% | |
| Q3 2021 | -7.7% | +3.8% | -9.7% | |
| Q4 2020 | -4.1% | -6.2% | -26.3% | |
| Q2 2021 | -0.3% | -6.5% | -29.4% | |
| Q2 2020 | -0.3% | -6.5% | -29.4% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro